Interferons (IFNs), produced during viral infections, induce the expression of hundreds of stimulated genes (ISGs). Some ISGs have specific antiviral activity while others regulate the cellular 20 response. In addition to functioning as an antiviral effector, IFN-stimulated gene 15 (ISG15) is a 21 negative regulator of IFN signalling and inherited ISG15-deficiency leads to autoinflammatory 22 interferonopathies where individuals exhibit elevated ISG expression in the absence of infection. We 23 have recapitulated these effects in cultured human A549-ISG15 -/cells and (using A549-UBA7 -/cells) 24 confirmed that posttranslational modification by ISG15 (ISGylation) is not required for regulation of 25 the type-I IFN response. ISG15-deficient cells pre-treated with IFN-α were resistant to paramyxovirus 26 infection. We also showed that IFN-α treatment of ISG15-deficient cells led to significant inhibition 27 of global protein synthesis leading us to ask whether resistance was due to the direct antiviral 28 activity of ISGs or whether cells were non-permissive due to translation defects. We took advantage 29 of the knowledge that IFN-induced protein with tetratricopeptide repeats 1 (IFIT1) is the principal 30 antiviral ISG for parainfluenza virus 5 (PIV5). Knockdown of IFIT1 restored PIV5 infection in IFN-α-31 pre-treated ISG15-deficient cells, confirming that resistance was due to the direct antiviral activity of 32 the IFN response. However, resistance could be induced if cells were pre-treated with IFN-α for 33 longer times, presumably due to inhibition of protein synthesis. These data show that the cause of 34 virus resistance is two-fold; ISG15-deficiency leads to the 'early' over-expression of specific antiviral 35
Introduction 38
The innate immune response against pathogens is underpinned by the evolutionary conserved 39 interferon (IFN) system. All cells express pathogen recognition receptors (PRRs) that sense the 40 products of infection and establish a signalling cascade leading to the production of cytokines, 41 including type I IFN (IFN-α/β) (1, 2) . IFN is secreted from cells and binds to cell surface receptors 42 expressed on both infected and non-infected cells, initiating a JAK/STAT signalling cascade, 43 culminating in the expression of hundreds of interferon stimulated genes (ISGs) (3). The biological 44 effects of ISGs are extensive and their principle role is to generate an unfavourable environment for 45 the replication of viruses. Many ISGs have broad antiviral activity, such as double-stranded RNA 46 dependent protein kinase (PKR) that, upon recognition of viral dsRNA, dampens general protein 47 synthesis and prevents the translation of viral mRNAs (4). Other antiviral ISGs, such as IFN-induced 48 protein with tetratricopeptide repeats (IFIT) proteins, inhibit specific viruses, but for many, they are 49 inconsequential (5). Additionally, multiple ISGs are generally required to limit infection because the 50 majority of ISGs result in low to moderate levels of inhibition (6); however, ISGs with specific 51 antiviral properties for a given virus are usually not known. Nevertheless, the nature of the innate 52 immune response necessitates the production of the complete spectrum of ISGs, albeit with a high 53 degree of redundancy, as during a natural infection, the identity of the infecting virus is not known. 54
This response is inevitably tightly regulated, as a dysregulated response leads to a suite of 55 autoinflammatory diseases (7) . 56
The ubiquitin-like protein (Ubl) ISG15 is strongly induced by IFN and is critical for regulating how cells 57 respond to infection. As a posttranslational modification (PTM), it can covalently modify proteins in a 58 process known as ISGylation, and in many cases, modification of viral proteins forms part of the 59 antiviral response (8). Covalently bound ISG15 can also be removed from proteins by the ubiquitin 60 specific protease USP18 (9). Importantly, loss-of-function mutations in ISG15 have been identified in 61 human patients with subsets of autoinflammatory interferonopathies and typically these individuals 62 demonstrate elevated ISG expression in the absence of infection (10). Mechanistically, it was shown 63 that ISG15 functions as a negative regulator of type I IFN signalling by stabilising USP18, a known 64 inhibitor of JAK/STAT signalling (11) (12) (13) . Intriguingly, despite the known functions of ISG15 and 65 USP18 in the ISGylation process, the regulation of type I IFN signalling was entirely independent of 66 ISGylation (10). Interestingly, mouse Isg15 is not required to stabilise Usp18 and appears not to be 67 needed to regulate IFN signalling, suggesting a species-specific, gain-of-function for human ISG15 68 (although other species have not yet been tested) (14) . 69
Previous work has shown that cells from ISG15-deficient patients expressed higher levels of ISGs 70 compared to normal controls when treated with recombinant IFN-α and these cells were resistant to 71 several viruses (14); however, it was not clear at what stage of infection viruses were blocked nor 72
how. Furthermore, cells were treated with IFN-α followed by washing (to remove IFN) and rested for 73 36 hours prior to infection. Since ISG15 is involved in regulating the cell cycle (15) and protein 74 synthesis (shown in this report), an over-amplified IFN response (due to lack of ISG15 and reduced 75 levels of USP18) may have led to virus resistance simply because cells were no longer permissive to 76 infection. This has implications for our understanding as to why ISG15-deficient patients are not 77 more susceptible to viral infections; these observations have led to the suggestion that, unlike in 78 mice, human ISG15 is not an antiviral effector (14, 16). 79 In this study, we recapitulated the phenotype observed in ISG15-deficient patient cells upon 80 treatment with recombinant IFN-α2b in a cell culture model and dissected the mechanisms that 81 result in virus resistance during an antiviral state. We showed that resistance was due to the direct 82 antiviral activity of the type I IFN response and discuss the implications of ISG15-loss-of-function 83 during the innate immune response. Based on our findings, we conclude that observations from 84 ISG15-deficient patients alone cannot be used to infer that ISG15 does not possess antiviral effector 85 functions, as has been proposed (14, 16) . 86 87
Materials and methods 88
Cells 89
Vero cells (African green monkey kidney epithelial cells) and A549 cells (human adenocarcinoma 90 alveolar basal epithelial cells), and derivatives, were maintained in Dulbecco's modified Eagles's 91 medium (DMEM; Sigma) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS, 92 Biowest) and incubated in 5% (v/v) CO2 at 37°C in a humidified incubator. A549-shIFIT1 have been 93 described elsewhere (17) and were maintained in blasticidin (10 µg/ml). A549-ISG15 -/cells were 94 generated by CRISPR/Cas9n system that utilises the D10A dual 'nickase' mutant of Cas9 (Cas9n) that 95 ostensibly limits off-target effects. Briefly, to disrupt exon 2 of the ISG15 gene, single guide RNA 96 (sgRNA) sequences were cloned using the pPX460 and transfected into A549 cells as previously 97 described (18). Transfectants were enriched after 48 h by treating cells with puromycin (1 μg/ml) for 98 2 d and then diluted to single cells in 96-well plates. Correctly edited cell clones were verified by 99 immunoblot analysis. A549-ISG15 -/--shIFIT1 cells were generated as previously described using A549-100 ISG15 -/-(B8) and maintained in media with blasticidin (10 µg/ml) (17). To generate A549-UBA7 -/-101 cells, A549 cells were first made to stably express Streptococcus pyogenes Cas9 following blasticidin 102 selection of cells transduced with lentiCas9-Blast (gift from Feng Zhang, Addgene plasmid # 52962 103 (19) ). The sgRNA sequence that targeted exon 3 of UBA7 was chosen computationally 104 (https://www.deskgen.com) and complementary oligonucleotides (sense: 105 caccGCACACGGGTGACATCACTG; antisense: aaacCAGTGATGTCACCCGTGTGC) were hybridised and 106 ligated into the Bsm BI site of pLentiGuide-Puro (gift from Feng Zhang, Addgene # 52963 (20) ). Cas9-107 expressing A549s were transduced with UBA7 sgRNA-expressing lentiGuide-Puro and selected with 108 puromycin. Puromycin-resistant cells were single-cell cloned by FACS and successful knockout cells 109 were validated by immunoblot analysis. A549-Npro cells have been described previously (21) . 110
Virus infections and treatments. 111
Viruses used were human parainfluenza virus 2 (HPIV2) strain Colindale (HPIV2-Co), HPIV3 strain 112 Washington/47885/57 (HPIV3-Wash) (20), PIV5 strain W3 (PIV5-W3) (22) and PIV5 strain CPI-(PIV5-113 CPI-) (23). Virus stocks were prepared by inoculating Vero cells at a multiplicity of infection (MOI) of 114 0.001 with continual rocking at 37°C. Supernatants were harvested at 2 d p.i., clarified by 115 centrifugation at 3,000 xg for 15 min, aliquoted and snap-frozen. Titres were estimated by standard 116 plaque assay on Vero cells in 6-well plates. 117
For infection studies, cell monolayers were infected in 6-well plates with virus diluted in medium to 118 achieve a MOI of 10, unless stated otherwise. Virus adsorption was for 1 h, after which the viral 119 inoculum was removed and replaced with media supplemented with 2% (v/v) FBS and incubated in 120 5% (v/v) CO2 at 37°C until harvested. When cells were treated with IFN-α prior to infection (pre-121 treated) this was done with 1000 IU/ml IFN-α2b (IntronA, Merck Sharp & Dohme Ltd.) 18 h prior to 122 infection, unless otherwise stated. IFN-α remained on cells for the duration of experiments. Cells 123 were either processed for immunoblot analysis or (if infecting with rPIV5-mCherry, kind gift of Dr He, 124
University of Georgia, USA) imaged using an IncuCyte Zoom imaging system (Sartorius). 125
For plaque assays 30-40 PFU PIV5-CPI-in 1 ml DMEM, 2% FBS were adsorbed for 1 h onto confluent 126 monolayers of cells in 6-well plates while rocking at 37°C. Following adsorption, 2 ml overlay 127 (DMEM, 2% FBS, Avicel) was added to wells and incubated for 6 d. Cells were fixed with 5% 128 formaldehyde (10 min), washed in PBS and permeabilised for 10 min (PBS, 1% Triton X-100, 3% FBS) 129 washed again and incubated for 1 h with a pool of PIV5-specific antibodies (24) diluted in PBS, 3% 130 
ISG15-knockout A549 cells recapitulate ISG15-deficient patient cells 176
Among the several immune modulatory roles of ISG15 (8), intracellular ISG15 expression, at least in 177 human cells, is critical for regulating the magnitude of the type I IFN response (10, 14) . To investigate 178 the pleotropic nature of human ISG15 we developed cell lines that lack ISG15 expression. Because of 179 our interest in respiratory viruses, including paramyxoviruses, we chose to knockout ISG15 180 expression in the lung adenocarcinoma cell line A549 by CRISPR/Cas9 genome editing as described 181 previously (18). Furthermore, A549 cells have proved to be a very useful model for understanding 182 virus-IFN interactions. The resulting culture was single cell cloned and ISG15 expression was 183 assessed by immunoblotting three clones (B8, B6 and C4). We also selected a clone that had gone 184 through the CRISPR/Cas9 process but retained ISG15 expression (C4+) (Fig. 1a ). In addition to control 185 A549 cells, all clones were treated with IFN-α for 24 h, 48 h or left untreated. Immunoblot analysis 186 showed that, compared to control cells, expression of the ISG MxA was higher in A549-ISG15 -/cells 187 ( Fig. 1a ). We also tested the impact of ISG15-deficiency on the expression of various ISG mRNAs. For 188 this, we selected clone B8 for further analyses; these cells were, in addition to control A549 cells, 189 treated with IFN-α, or left untreated, for 24 h and the expression of various ISGs were examined by 190 RT-qPCR. Whilst IFN-α treatment enhanced the expression of all ISGs tested, this increase was larger 191 in ISG15-deficient cells compared to control A549 cells (between 5-and 10-fold, depending on the 192 ISG) ( Fig. 1b) . Importantly, the expression of ISGs in non-stimulated cells was equivalent to control 193 cells suggesting that ISG15-dependent regulation is specific to the IFN response and not required for 194 the regulation of basal gene expression. Further experiments showed that lack of ISG15 prolonged 195 the longevity of ISG protein expression, which presumably has an impact on patients with 196 autoinflammatory diseases associated with ISG15 loss-of-function. Here, control A549 and knockout 197 cells were treated with IFN-α for 24 h. The cells were washed and media (without IFN-α) was then 198 added. Cells were harvested every 24 h for 96 h and MxA expression was assessed by 199 immunoblotting (Fig. 1c ). In control A549 cells MxA expression peaked at 24 h (the point at which 200 IFN was removed) and had returned to basal levels between 72 and 96 h. In knockout cells MxA 201 expression was clearly higher than in control cells, corroborating our mRNA analyses. Furthermore, 202
while MxA expression in A549-ISG15 -/did recede between 72 and 96 h, high protein levels remained 203 at 96 h. A dysregulated IFN response in ISG15-deficient cells is thought to be due to destabilisation 204 of USP18, a known negative regulator of JAK/STAT signalling (10). To determine if USP18 is similarly 205 affected in our cell lines, A549-ISG15 -/cells were treated with IFN-α for 24 or 48 h (or left untreated) 206 and whole cell lysates were probed for USP18 by immunoblotting. USP18 was robustly induced in 207 A549 cells following IFN-α treatment; however, levels of USP18 were much lower in IFN-α-treated 208 ISG15-deficient cells (Fig. 1d ). USP18 mRNA levels were approximately 10-fold higher in IFN-treated 209 ISG15-deficient cells compared to control A549s, demonstrating that reduced USP18 in A549-ISG15 -/-210 cells was not due to reduced transcription ( Fig. 1b ). Together, these data show that ISG15 is critical 211 for the regulated expression of ISGs. Moreover, they demonstrate that the effects of IFN treatment 212 on our ISG15 knockout A549 cell lines recapitulate the findings in cells derived from ISG15-deficent, 213 patient cells. 214
215

ISG15-deficiency leads to translational repression following IFN treatment 216
During our studies we observed that IFN-α-treatment of ISG15-knockout cells led to a reduction in 217 protein synthesis and reasoned that this was a likely contributor to the reported virus resistance in 218 ISG15-deficient cells (14). To investigate this we treated, or left untreated, A549 and A549-ISG15 -/-219 (B8) cells with IFN-α. At 24 h, 48 h and 72 h following treatment cells were pulse labelled with 35 S-220
Methionine ( 35 S-Met) for 1 h and the incorporation of 35 S-Met was analysed by phoshoimager 221 analysis. These data showed, compared to control cells, that there was a pronounced decrease in 222 protein synthesis in ISG15 -/cells between 24 h and 48 h ( Fig. 2a ). Furthermore, when cells were pre-223 treated with IFN-α for 8 h, or left untreated, infected with the orthorubulavirus PIV5 (family 224
Paramyxoviridae, sub-family Orthorubulavirinae) at a MOI of 10 and then labelled for 1 h with 35 S-225 Met at 24 h and 48 h p.i. (32 h and 56 h post IFN-α treatment, respectively), there was no evidence 226 of viral protein synthesis in treated A549-ISG15 -/cells, whereas in treated control cells, viral protein 227 synthesis was evident at 48 h p.i. (Fig. 2b) . These data demonstrate that IFN-treatment of A549-228 ISG15 -/cells led to inhibition of protein synthesis that was associated with viral resistance, at least at 229 later times. (14), and this seems to extend to PIV5 with our in vitro system 236 ( Fig. 2b ). To investigate this in A549-ISG15 -/cells, control A549 cells and the ISG15 knockout clones 237 described above were either untreated or treated with 1000 IU/ml IFN-α2b (the same concentration 238 and IFN-α type used in (14)) for 18 h. Cells were then infected with PIV5 (strain W3) (22) for 24 and 239 48 h and analysed by immunoblotting. In all cell lines, the levels of PIV5 nucleoprotein (NP) 240 expression was equivalent at 24 and 48 h in unstimulated cells (Fig. 3a) . In IFN-α pre-treated control 241 cells, including C4+ that retained ISG15 expression, the level of NP expression was markedly reduced 242 at 24 h. By 48 h, the level of NP increased showing that infection had progressed even in the 243 presence of IFN-α (Fig. 3a) . This is because the PIV5-V protein targets STAT1 for proteasomal 244 degradation, and once sufficient V is expressed, the IFN response is dismantled allowing the virus to 245 replicate (23). However, all A549-ISG15 -/cell lines that had been pre-treated with IFN-α were 246 resistant to PIV5 infection as shown by dramatically reduced, or even absent, NP expression at both 247 time points (Fig. 3a) . 248
Previous reports have shown that the ISG15 regulation of IFN signalling is independent of its ability 249 to covalently modify proteins by ISGylation (10). To confirm this, we again applied CRISPR/Cas9 250 genome engineering technology and knocked out expression of UBA7, the E1 enzyme required for 251
ISGylation. For this we took a different approach compared to generating our ISG15 knockout cells 252 (19) . Here, we introduced constitutive expression of Cas9 by lentiviral transduction of A549 cells and 253 transduced A549-Cas9 cells with lentiGuide-Puro lentivirus carrying a guide RNA specific for UBA7, 254 followed by single-cell cloning. We confirmed that all clones were UBA7-deficient by immunoblot 255 analysis, which demonstrated that they retained expression of ISG15 but had lost the ability to 256 ISGylate proteins (Fig. 3b ). Additionally, following the scheme used in Fig. 3a , these cells were 257 infected with PIV5-W3. These data showed that, compared to ISG15 knockout cells that were 258 resistant to infection, all IFN-α-pre-treated UBA7-knockout cells were infected as efficiently as 259 control cells (Fig. 3b ), confirming reports that ISG15-dependent regulation of type I IFN signalling 260 does not require ISGylation (10). 261
262
The direct antiviral activity of ISGs is responsible for virus resistance 263 Virus resistance can be induced following 8 h IFN-α treatment (shorter times were not tested), well 264 before any obvious effect on global protein synthesis (Fig. 2) . Therefore, shutdown of translation is 265 unlikely to be the sole contributor to virus resistance at early time points and so we wished to 266 determine whether the direct antiviral activity of ISGs was responsible. Addressing this question is 267 complex since, for most viruses, the specific ISG(s) responsible for blocking replication is not known. 268
However, for PIV5, it has been established that IFIT1 is the principle ISG responsible for most of the 269 IFN-dependent antiviral activity (17, 26) . We therefore hypothesised that if virus resistance was 270 caused by the direct antiviral activity of ISGs, knockdown of IFIT1 in ISG15-deficient cells would 271 permit PIV5 replication during an antiviral response. We reduced IFIT1 (according to (17)) in A549 272 and A549-ISG15 -/cells and all four cell lines (A549, A549-ISG15 -/and the respective shIFIT1 cells) 273 were pre-treated, or left untreated, with IFN-α and then infected with PIV5-W3 (MOI 10) for 24 and 274 48 h. Expression of PIV5 NP, analysed by quantitative immunoblotting, was used to measure virus 275 infection (Fig. 4a ). IFIT1 levels and expression of ISG15 were likewise tested. Typically, pre-treatment 276 of naïve cells with IFN-α reduces infection, as shown by a reduction in NP levels, compared to non-277 treated cells (Fig. 2b & 3a) ; nevertheless, because PIV5 expresses the IFN antagonist V protein, NP 278 levels reach similar levels to untreated cells by 48 h p.i. However, this IFN-dependent reduction in 279 virus infection is diminished when IFIT1 is knocked down, confirming earlier reports of IFIT1's 280 antiviral activity against PIV5 (17, 26) . While IFN- pre-treatment of A549-ISG15 -/cells renders them 281 resistant to infection, when IFIT1 was also knocked down, PIV5 infection was restored (Fig. 4a ). 282
Because we performed quantitative immunoblotting of NP and β-Actin, we were able to quantify NP 283 levels, allowing us to analyse these changes statistically (Fig. 4b) . These data show that in IFN-α-pre-284 treated cells, knocking IFIT1 down restored NP to similar levels to those seen in untreated cells, 285 regardless of ISG15 status. 286
Rather than solely relying on viral protein expression as a surrogate for virus infection, we also 287 tested virus replication using a biologically relevant plaque assay (Fig. 4c ). Cells were infected with 288 approximately 30-40 PFU of PIV5 stain CPI-(PIV5-CPI-) (27), a strain unable to block IFN signalling 289 due to a mutation in its V protein. Infected cells were fixed 6 d p.i. and stained for viral antigen. As 290 previously demonstrated (17), PIV5-CPI-was unable to efficiently form plaques in IFN-competent 291 A549 cells. However, PIV5-CPI-did replicate when cells were unable to produce IFN, such as in A549-292 Npro cells that constitutively express bovine viral diarrhea virus (BVDV) Npro that cleaves IRF3 (a 293 transcription factor critical for IFN induction (21)). Furthermore, when IFIT1 was knocked down, 294 PIV5-CPI-was able to replicate (albeit less efficiently), further highlighting the major role of IFIT1 as 295 an anti-PIV5 protein. As expected, and like A549 cells, there was very little virus replication in A549-296 ISG15 -/cells; however, when IFIT1 was knocked down, cells were able to support virus replication. It 297 must be noted however that virus replication in A549-ISG15 -/-/shIFIT1 cells did not recover to the 298 same degree as A549-shIFIT1 cells. We propose that the reason for this will be complex and may 299 include the likelihood that additional, yet to be identified, anti-PIV5 ISGs exist which are expressed at 300 higher levels in ISG15-deficient cells. Another possible explanation is the inhibition of protein 301 synthesis, including that of viral proteins, in ISG15-deficent cells; cells were infected for 6 days prior 302 to performing the plaque assays, a time point beyond that required to observe a significant effect on 303 protein synthesis ( Fig. 2a ). Therefore, the plaques observed in A549-ISG15 -/-/shIFIT1 cells likely result 304 from virus that replicated prior to the inhibition of global protein synthesis. 305
We also investigated infection of these cell lines with other paramyxoviruses whose sensitivity to 306 IFIT1 has been previously reported. Cells were treated with IFN-α and then infected with HPIV2 307 strain Colindale (MOI 10; family Paramyxoviridae, sub-family Orthorubulavirinae), which is reported 308 to be moderately sensitive to IFIT1-restriction (26), for 24 and 48 h (untreated cells were not 309 analysed because of high cytopathic effect in the absence of IFN). To investigate infection, we 310 detected expression of HPIV2 phosphoprotein by quantitative immunoblotting (Fig. 5a ), which 311 showed that IFN-α-pre-treated A549-ISG15 -/cells were largely resistant to infection, although by 48 312 h p.i. there was some, albeit low level, evidence of viral protein accumulation. Nevertheless, 313 infection of A549-ISG15 -/-/shIFIT1 did allow significantly more viral protein expression. Quantitative 314 analyses demonstrated that viral protein accumulation in A549-ISG15 -/-/shIFIT1 cells was significantly 315 higher than in A549-ISG15 -/cells, but this was not as high as in A549 control cells, which agrees with 316 the reported partial sensitivity of HPIV2 to IFIT1 restriction indicating that additional ISGs target 317 HPIV2 (Fig. 5b) . We performed a similar analysis with HPIV3 strain Washington (20) (family 318
Paramyxoviridae, sub-family Orthoparamyxovirinae), a virus reported to have limited sensitivity to 319 IFIT1 (26). Interestingly, pre-treatment of A549 and A549-shIFIT1 cells with IFN-α had less of an 320 effect on virus protein accumulation compared to the effects on PIV5 infection (Fig. 5c ). 321
Furthermore, while infection of IFN-α-pre-treated ISG15 knockout cells significantly reduced 322 infection compared to control cells, virus infection in these cells was still more robust compared to 323 PIV5 and HPIV2-infected cells. Nevertheless, knockdown of IFIT1 only slightly increased HPIV3 324 protein expression in both ISG15-competent and ISG15-deficient cells (Fig. 5d ), supporting reports of 325 a minor role of IFIT1 during the antiviral response to HPIV3 (26). 326
Our data have so far suggested that early virus resistance is mediated by the direct antiviral activity 327 of the IFN response. However, protein synthesis is reduced at later times post-IFN treatment and 328 this is likely to cause resistance; therefore, we investigated whether PIV5 resistance could be 329 induced independently of the direct antiviral activity of IFIT1. To do this we pre-treated the four cell 330 lines (A549, A549-shIFIT1, A549-ISG15 -/and A549-ISG15 -/--shIFIT1) with IFN-α for different periods of 331 time, infected with a recombinant PIV5 that expresses the fluorescent protein mCherry (rPIV5-332 mCherry) for 48 h (MOI 10) and measured fluorescence as a marker of virus replication (Fig. 6a) . 333
Virus replication in A549 cells was equivalent regardless of the time cells had been pre-treated with 334 IFN-α and, as expected, A549-ISG15 -/cells were resistant to infection at any time post IFN-α 335 treatment (Fig. 6b) . Any advantage to PIV5 replication as a result of IFIT1 knockdown in A549-shIFIT1 336 cells was lost when cells had been pre-treated for 16 h or more, as longer periods of pre-treatment 337 resulted in replication equivalent to IFN-pre-treated A549 cells. Similarly, PIV5 replication in A549-338 ISG15 -/--shIFIT1 cells was higher than A549 control cells, and equivalent to A549-shIFIT1 cells, 339 following 8 and 16 h pre-treatment; however, when cells were pre-treated for 24 h, replication was 340 lower than in A549 and A549-shIFIT1 cells. Interestingly, as the time of pre-treatment of A549-ISG15 -341 /--shIFIT1 cells extended, virus replication reduced further until cells became resistant (e.g. at 60 h 342 and 72 h pre-treatment, Fig. 6b) , which was not observed in A549 or A549-shIFIT1 cells. These data 343 suggest that cell permissiveness progressively reduced with longer times of IFN-α pre-treatment, 344 which correlated with the effects of IFN-α treatment on protein synthesis in ISG15-deficient cells 345 (Fig. 2) . 346
A previous report demonstrated that ISG15-dependent stabilisation of USP18 was required to bring 347 about regulation of the type I IFN response and this was sufficient for these cells to once again be 348 infected (14) . However, what aspects of the antiviral response was responsible for resistance was 349 not investigated. Taken together, these data strongly suggest that virus resistance in early IFN- Previous work had shown that virus resistance was observed in cells that had been treated with IFN-358 α and then left to rest for 36 h prior to challenge (14). We had observed that IFN-α treatment of 359 A549-ISG15 -/cells led to dramatic decreases in protein synthesis, particularly between 24 and 48 h; 360 therefore, it was not clear whether the initially reported virus resistance was due to defects in 361 translation (including of viral mRNAs) at the timepoint used in (14) or due to the direct antiviral 362 activity of the IFN response. For most viruses, the specific ISG(s) with antiviral activity for a given 363 virus is not known, making the latter difficult to discern; however, for PIV5, it is well established that 364 IFIT1 is responsible for the majority of the antiviral response (17). To study this we generated A549-365 ISG15 -/cells and showed these cells recapitulated the effects observed in ISG15-deficient patient 366 cells following treatment with IFN-α which included dysregulated ISG expression and reduced USP18 367 protein levels following IFN-α treatment (Fig. 1) . Additionally, by knocking-out UBA7, the first 368 enzyme in the ISGylation cascade, we showed that ISGylation is not required for a regulated 369 response (Fig. 3b) , confirming previous reports that 'free' ISG15 is required for regulation (10). 370
Using these cell lines in combination with a PIV5 infection model, we showed that infection of IFN-α-371 pre-treated ISG15-deficient cells in which IFIT1 had been knocked down restored infection, thus 372 confirming that at early times post infection, resistance was indeed due to the direct antiviral activity 373 of the IFN response. Furthermore, because IFIT1 blocks the translation of viral transcripts, our data 374 suggest that IFN-treated A549-ISG15 -/cells were still susceptible to infection, allowing viral 375 transcription to take place prior to IFIT1 restriction, and that ISG15 was unlikely to significantly 376 regulate processes involved in entry. Nevertheless, if ISG15-deficient cells were treated for longer 377 periods with IFN-α prior to infection they did become resistant, even when IFIT1 was knocked down, 378 suggesting that at later times the inhibition of protein synthesis was the principal cause of 379 resistance. These data suggest that the virus resistance reported by Speer et al. (14) was due to a 380 lack of permissiveness and not a result of the direct antiviral activity of the IFN response, although 381 different cells were used in that study. 382
The data here demonstrate that the mechanism of resistance is likely two-fold, depending on the 383 duration that cells are exposed to IFN-α. It is not currently possible to know which mechanism is 384 dominant in ISG15-deicient patients, but it is likely to be a combination of both. Nevertheless, virus 385 resistance results from a lack of IFN signalling control -as a consequence of ISG15-loss-of-function -386 which would explain why ISG15-deficient patients were not more susceptible to severe infection. 387
This observation, therefore, cannot be used to support the notion that human ISG15 does not 388 possess direct antiviral activity, as proposed (14, 16) . It is likely that many viruses will not be 389 sensitive to ISG15-dependent antiviral activity; however, this is true of many antiviral effectors. For 390 example, and as confirmed in this study, IFIT1 strongly restricts PIV5 infection, yet it has reduced 391 activity against HPIV2 and likely no activity against HPIV3 or human respiratory syncytial virus (26). It 392 is also true that several ISGs are often required to limit infection (6); therefore, if one antiviral 393 effector mechanism is absent (such as ISGylation), there is sufficient redundancy to avoid severe 394 effects of infection (redundancy that can complicate the investigation of specific antiviral 395 mechanisms in in vitro studies). Nevertheless, several human viruses have been shown to be 396 sensitive to ISGylation and many have evolved specific mechanisms to counteract antiviral 397 ISGylation, adding further weight to the argument that human ISG15 does have antiviral activity 398 (reviewed in (8)). Indeed, other than the handful of patients that have been found to lack ISG15 399 expression (10, 28), individuals will possess an intact IFN response where the antiviral activity of 400 ISG15 (and other effectors) will function, if the infecting virus is sensitive to it. 401
It was surprising that protein synthesis was so affected in ISG15-deficient cells following IFN 402 treatment. It is well established that inhibition of general protein translation is a key feature of the 403 antiviral response and this is through the actions of proteins such as PKR or PERK (PKR-like ER kinase) 404 (4). However, for PKR to be activated it must recognise dsRNA, which was absent in IFN-α-treated 405 cells. Similarly, PERK is activated upon endoplasmic reticulum stress which might be expected during 406 a viral infection, but not following treatment with IFN alone. Previous reports have shown that 407 carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has antiviral activity against 408 human cytomegalovirus, influenza virus and metapneumovirus by supressing mTOR-mediated 409 protein synthesis (29, 30) . The membrane protein CEACAM1 is induced by innate sensors such as 410 TLR-4 (31) and IFI16 (30) and delivers inhibitory signals via SHP1 (haematopoietic cells) or SHP2 411 (epithelial and endothelial cells) phosphatase activity through CEACAM1 immunoreceptor tyrosine-412 based inhibitory motifs (ITIMs) (32). CEACAM1 expression is rapidly induced following activation of 413 NF-κB and IRF1, but whether IFN-α alone (as used here) can induce it expression is not clear. The 414 IRF1 promoter possesses a single GAS element, but no IRES, and so its expression is induced by 415 STAT1 homodimers (33). Type I IFN signalling predominantly leads to the formation of STAT1-STAT2 416 heterodimers that associate with IRF9 (to form the ISGF3 transcription factor) to drive expression of 417
ISGs that possess IRES elements in their promoters; however, STAT1 homodimers are formed after 418 type I IFN treatment, but these are at lower concentrations. It is possible that 'late' inhibition of 419 protein synthesis in ISG15-deficient cells (compared to the swifter antiviral activity of IRES-420 containing genes such as IFIT1) may relate to the kinetics of CEACAM1 expression as the 421 accumulation of STAT1 homodimers is required to drive the expression of IRF1, that itself needs to 422 be translated before it induces CEACAM1. Of course, the accumulation of STAT1 homodimers may 423 be higher in ISG15-deficient cells because of a dysregulated type I IFN response. Nevertheless, it is 424 plausible that the overamplified type I IFN response in ISG15-deficient cells led to high levels of 425 CEACAM1 (compared to control cells) resulting in inhibition of protein synthesis. Moreover, ISG15 426
may have yet-to-be characterised functions in regulating the cellular response to stressors that lead 427 to inhibition of protein synthesis. 428
It has been reported that ISG15 has a role in regulating the cell cycle through its interactions with 429 SKP2 and USP18, although experiments in that study were not performed in IFN-treated cells, nor 430 were ISG15 knockout cells tested (15) . While rates of protein synthesis differ during different stages 431 of the cell cycle, translation is thought to be lowest during mitosis (34) . Perturbation of the ISG15-432 SKP2-USP18 axis following ablation of USP18 led to a delayed progression from G1 to S phase which 433 is not generally thought to be associated with translational repression (35). Of note, we have not 434 observed any obvious differences in cell growth in non-treated A549-ISG15 -/cells. Further work is 435 required to dissect the mechanism responsible for ISG15's effects on general protein translation 436 during an antiviral response. 437 ISG15 has emerged as a central regulator of immunity. It is a pleotropic protein that is strongly 438 expressed following activation of innate immune sensors and connects innate and adaptive 439 immunity. In this study, we have shown that a lack of ISG15 leads to virus resistance by two 440 kinetically distinct mechanisms; the rapid induction of antiviral ISGs and the unexpected effects on 441 protein synthesis. Our newly developed cell lines and infection model will pave the way for further 442 studies investigating the regulatory mechanisms of ISG15 during the antiviral response. untreated and then infected with PIV5 strain W3 (MOI = 10). Cells were harvested at 24 h and 48 h 482 p.i. and processed for immunoblot analysis using antibodies specific for PIV5 nucleoprotein (NP), 483 ISG15, MxA and β-Actin. This experiment was independently performed twice. (b) UBA7 knockout 484 cells were generated using CRISPR/Cas9 genome editing; Cas9-expressing A549 cells were first 485 generated (following transduction with lentiCas9-Blast) and then transduced with lentiGuide-Puro 486 expressing a single guide RNA that targeted exon 3 of the UBA7 gene. Knockout cells were single-cell 487 cloned and three were selected for further analysis. These cells were treated with IFN-α, infected 488 and processed as in (a) using antibodies specific for PIV5 NP, ISG15, UBA7 and β-Actin. This 489 experiment was independently performed twice. 490 491 Fig. 4 . Direct antiviral activity of ISGs is responsible for virus resistance due to ISG15-loss-of-function. 492 (a) IFIT1 was constitutively knocked down in A549 or A549-ISG15 -/-(B8) cells following a previously 493 described method (17). A549, A549-ISG15 -/-(B8) and the corresponding IFIT1 knockdown cells were 494 treated with IFN-α, infected with PIV5 and processed as in Fig. 3a . Following immunoblotting with 495 specific antibodies, PIV5 NP and β-Actin were detected using near-infrared (NIR) dye-conjugated 496 secondary antibodies to facilitate quantification. IFIT1 and ISG15 proteins were detected using 497 chemiluminescence following incubation with horseradish peroxidase (HRP)-conjugated secondary 498 antibodies. (b) Experiments described in (a) were performed independently three times (infections 499 were performed on three separate occasions) and NP and β-Actin levels were quantified using Image 500 Studio software (LiCOR). Signals were relative to those generated from IFN-α-treated A549 cells 501 infected for 48 h p.i. (set to 100%). Error bars represent the standard deviation of the mean from the 502 three experiments. ** indicates P < 0.01 using Student's t test. (c) Indicated cells were infected for 1 503 h with 30 -40 plaque forming units (PFU) of PIV5 (CPI-), a strain unable to block the IFN response 504 due to mutation in V. Monolayers were fixed 6 d p.i. Plaques were detected using a pool of anti-PIV5 505 antibodies specific for hemagglutinin (HN), nucleoprotein (NP), phosphoprotein (P) and matrix 506 protein (M) (see (24)). Plaque assays were performed on 3 independent occasions. 507 
